Harvard Breast Cancer – New Horizons – Current Controversies 2023 (Videos)

84 $

3 MP4 + 45 PDF Files

Category:

Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence and clinical skills of health care professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses and other clinicians involved in the care of breast cancer patients.
Learning Objectives
Upon completion of this activity, participants will be able to:

Apply knowledge of recent clinical data together with current expert recommendations to patient selection for new and emerging therapies for advanced breast cancer.
Apply knowledge in the treatment of breast cancer in special populations (including the elderly and young women) and adjust treatment decisions for specific patients as needed.
Select appropriate risk assessment modalities, where applicable and make evidence-based therapeutic selections for women who are candidates for neoadjuvant or adjuvant therapy and know the limitations of genomic testing.
Apply recent clinical data and expert recommendations to the management of women with breast cancer who are treated with mastectomy, including integration of surgical methods, breast reconstruction options and post-mastectomy radiation if needed.
Assess current practices with regard to symptom management during active treatment and in survivorship and consider the needs for fertility and lifestyle counseling among patients with breast cancer and survivors, and improve current practices if needed.
Evaluate the genetic and personal risk factors of breast cancer and utilize appropriate genetic testing for hereditary breast cancer.

Agenda

Thursday, July 20, 2023

8:00-8:15 AM

Welcoming Remarks
Harold Burstein, MD, PhD

SESSION I BREAST SURGERY

8:15-8:35 AM

Management of the Axilla
Monica Morrow, MD

8:35-8:55 AM

Reconstruction Options in 2023
Matthew Carty, MD

8:55-9:15 AM

Lymphatic Surgery
Michelle Coriddi, MD

9:15-9:30 AM

Q&A

9:30-9:55 AM

Lecture: The Future of Breast Cancer Pathology
Jorge Reis-Filho, MD, PhD, FRCPath

9:55-10:10 AM

Q&A

10:10-10:25 AM

Break

SESSION II GENETICS

10:25-10:45 AM

Prophylactic Surgery: Who, What, When?
Barbara Smith, MD, PhD

10:45-11:05 AM

Genetic Testing: Who, Which Test, When?
Judy Garber, MD, MPH

11:05-11:30 AM

Managing Hereditary Breast Cancer: What We Do; What We Still Don’t Know
Nadine Tung, MD

11:30-11:45 AM

Q&A

11:45 AM-1:00 PM

Lunch
*not provided

1:00-1:25 PM

Lecture: The Future of Breast Cancer Imaging and Screening
Constance Lehman, MD, PhD

1:25-1:40 PM

Q&A

SESSION III RADIATION THERAPY

1:40-2:00 PM

Schedules and Regimens
Jennifer Bellon, MD

2:00-2:20 PM

Postmastectomy Radiation
Rachel Jimenez, MD

2:20-2:40 PM

Oligometastatic Disease
Steven Chmura, MD, PhD

2:40-3:00 PM

Radiotherapy Options for Brain Metastases
Ayal Aizer, MD, MHS

3:00-3:15 PM

Q&A

3:15-3:30 PM

Break

3:30-3:55 PM

Lecture: The Future of Breast Cancer: Radiation Oncology
Bruce Haffty, MD, MS

3:55-4:10 PM

Q&A

4:10-5:10 PM

Tumor Board: Local Regional Therapy
Tari King, MD, FACS

Friday, July 21, 2023

SESSION IV ER POSITIVE BREAST CANCER

8:00-8:20 AM

Novel Agents: SERDS
Rinath Jeselsohn, MD

8:20-8:40 AM

Novel Agents: AKT Pathways
Alex Toker, PhD

8:40-9:00 AM

Male Breast Cancer
Jose Pablo Leone, MD

9:00-9:20 AM

Role of ADCs in ER+ Breast Cancer
Paolo Tarantino, MD

9:20-9:40 AM

Special Considerations in Premenopausal Women
Erica Mayer, MD, MPH

9:40-9:55 AM

Break

9:55-10:15 AM

Adjuvant Endocrine Therapy: How Long?
Heather Parsons, MD, MPH

10:15-10:35 AM

Adjuvant Therapy: CDK4/6 Inhibitors
Sarah Sammons, MD

10:35-10:55 AM

Adjuvant Therapy: Chemotherapy
Beverly Moy, MD, MPH

10:55-11:20 AM

Local Regional Considerations in Older Cancer Patients
Christina Minami, MD

11:20-11:35 AM

Q&A

11:35 AM-12:00 PM

Lecture: The Future of Breast Cancer Clinical Trials Designs
Nabihah Tayob, PhD

12:00-12:10 PM

Q&A

12:10-12:30 PM

Break

12:30-1:35 PM

Tumor Board: Advanced Breast Cancer
Moderator: Erica Mayer, MD, MPH
*Lunch Included

1:35-1:45 PM

Break

SESSION V TRIPLE NEGATIVE BREAST CANCER

1:45-2:05 PM

Where To With Immunotherapy
Sara Tolaney, MD, MPH

2:05- 2:25 PM

Treating Brain Metasteses
Nancy Lin, MD

2:25-2:45 PM

Antibody Drug Conjugates
Aditya Bardia, MD, MPH

2:45-3:10 PM

Lecture:The Future of Immunotherapy in Breast Cancer
Elizabeth Mittendorf, MD, PhD

3:10-3:20 PM

Q&A
Sara Tolaney, MD, MPH
Nancy Lin, MD
Aditya Bardia, MD, MPH
Elizabeth Mittendorf, MD, PhD

3:20-3:35 PM

Break

SESSION VI SURVIVORSHIP

3:35-3:55 PM

Pregnancy After Breast Cancer
Ann Partridge, MD, MPH

3:55-4:15 PM

Cannabinoids and Breast Cancer
Ilana Braun, MD

4:15-4:35 PM

Exercise, Diet and Breast Cancer
Jennifer Ligibel, MD

4:35-4:45 PM

Q&A
Ann Partridge, MD, MPH
Ilana Braun, MD
Jennifer Ligibel, MD

4:45-5:10 PM

Schlager Lecture: The Future of Breast Cancer and Genomic Tools and Testing
Fabrice Andre, MD, PhD

5:10-5:20 PM

Q&A

Saturday, July 22, 2023

TUMOR BOARD

8:00 – 9:00 AM

Tumor Board: Early Stage Breast Cancer
Hal Burstein, MD, PhD

9:00 – 9:30 AM

ASCO Highlights
Harold Burstein, MD, PhD

9:30 – 9:45 AM

Break

SESSION VII HER2 POSITIVE BREAST CANCER

9:45 – 10:05 AM

ADCs for HER2 Positive Tumors
Rachel Occhiogrosso Abelman, MD

10:05 – 10:25 AM

HER2 Testing
Laura Collins, MD

10:25 – 10:45 AM

Treatment for Early-Stage HER2 Positive Breast Cancer
Adrienne Waks, MD

10:45 -11:05 AM

Curing HER2+ Breast Cancer
Steven Isakoff, MD, PhD

11:05 – 11:20 AM

Q&A

11:20 -11:30 AM

Closing Remarks 
Harold Burstein, MD, PhD

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Related Products